Abstract
Poly(lactic-co-glycolic acid) microspheres loaded with imatinib mesylate has been developed as a new therapeutic strategy to prevent craniopharyngioma recurrence. Microspheres composed of different lactic/glycolic acid ratios, molecular weights and drug compositions were synthesized and loaded with imatinib mesylate by modified double-emulsion/solvent evaporation technique and subsequently characterized by particle-size distribution, scanning electron microscopy, encapsulation efficiency and in vitro drug release. Inhibitory potential of imatinib containing microspheres on tumor neovascularization was investigated on craniopharyngioma tumor samples by rat cornea angiogenesis assay. Results showed that microspheres in different LA:GA ratios [LA:GA 50:50 (G50), 75:25 (G25), 85:15 (G15)] considerably reduced neovascularization induced by recurrent tumor samples in an in vivo angiogenesis assay (P < 0.01). Our data indicate that local delivery of imatinib mesylate to the post-surgical tumoral cavity using biodegradable microspheres may be a promising biologically selective approach to prevent the recurrence of craniopharyngiomas, via inhibition of neovascularization.
References
Garnett MR, Puget S, Grill J, Sainte-Rose C. Craniopharyngioma. Orphanet J Rare Dis. 2007;2:18. doi:10.1186/1750-1172-2-18.
Karavitaki N, Brufani C, Warner JT, Adams CB, Richards P, Ansorge O, et al. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol (Oxf). 2005;62(4):397–409. doi:10.1111/j.1365-2265.2005.02231.x.
Symon L, Pell MF, Habib AH. Radical excision of craniopharyngioma by the temporal route: a review of 50 patients. Br J Neurosurg. 1991;5(6):539–49.
Yasargil MG, Curcic M, Kis M, Siegenthaler G, Teddy PJ, Roth P. Total removal of craniopharyngiomas. Approaches and long-term results in 144 patients. J Neurosurg. 1990;73(1):3–11.
Habrand JL, Ganry O, Couanet D, Rouxel V, Levy-Piedbois C, Pierre-Kahn A, et al. The role of radiation therapy in the management of craniopharyngioma: a 25-year experience and review of the literature. Int J Radiat Oncol Biol Phys. 1999;44(2):255–63.
Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1–18.
Vidal S, Kovacs K, Lloyd RV, Meyer FB, Scheithauer BW. Angiogenesis in patients with craniopharyngiomas: correlation with treatment and outcome. Cancer. 2002;94(3):738–45. doi:10.1002/cncr.10281.
Xu J, You C, Zhang S, Huang S, Cai B, Wu Z, et al. Angiogenesis and cell proliferation in human craniopharyngioma xenografts in nude mice. J Neurosurg. 2006;105(4 Suppl):306–10.
Xu J, Zhang S, You C, Wang X, Zhou Q. Microvascular density and vascular endothelial growth factor have little correlation with prognosis of craniopharyngioma. Surg Neurol. 2006;66(Suppl 1):S30–4. doi:10.1016/j.surneu.2006.05.047.
Sun HI, Akgun E, Bicer A, Ozkan A, Bozkurt SU, Kurtkaya O, et al. Expression of angiogenic factors in craniopharyngiomas: implications for tumor recurrence. Neurosurgery. 2010;66(4):744–50.
Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O’Reilly T, et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 2000;60(18):5143–50.
Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039–49.
Mu L, Feng SS. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release. 2003;86(1):33–48.
Okada H, Toguchi H. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst. 1995;12(1):1–99.
Lam XM, Duenas ET, Daugherty AL, Levin N, Cleland JL. Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes. J Control Release. 2000;67(2–3):281–92.
Cohen S, Yoshioka T, Lucarelli M, Hwang LH, Langer R. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res. 1991;8(6):713–20.
Whittlesey KJ, Shea LD. Delivery systems for small molecule drugs, proteins, and DNA: the neuroscience/biomaterial interface. Exp Neurol. 2004;190(1):1–16. doi:10.1016/j.expneurol.2004.06.020.
Lagarce F, Faisant N, Desfontis JC, Marescaux L, Gautier F, Richard J, et al. Baclofen-loaded microspheres in gel suspensions for intrathecal drug delivery: in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2005;61(3):171–80. doi:10.1016/j.ejpb.2005.04.004.
Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28(1):5–24.
Benny O, Duvshani-Eshet M, Cargioli T, Bello L, Bikfalvi A, Carroll RS, et al. Continuous delivery of endogenous inhibitors from poly(lactic-co-glycolic acid) polymeric microspheres inhibits glioma tumor growth. Clin Cancer Res. 2005;11(2 Pt 1):768–76.
Yemisci M, Bozdag S, Cetin M, Soylemezoglu F, Capan Y, Dalkara T, et al. Treatment of malignant gliomas with mitoxantrone-loaded poly (lactide-co-glycolide) microspheres. Neurosurgery. 2006;59(6):1296–302. doi:10.1227/01.NEU.0000245607.99946.8F. discussion 302-3.
Benny O, Menon LG, Ariel G, Goren E, Kim SK, Stewman C, et al. Local delivery of poly lactic-co-glycolic acid microspheres containing imatinib mesylate inhibits intracranial xenograft glioma growth. Clin Cancer Res. 2009;15(4):1222–31. doi:10.1158/1078-0432.CCR-08-1316.
Ong BY, Ranganath SH, Lee LY, Lu F, Lee HS, Sahinidis NV, et al. Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme. Biomaterials. 2009;30(18):3189–96. doi:10.1016/j.biomaterials.2009.02.030.
Ranganath SH, Fu Y, Arifin DY, Kee I, Zheng L, Lee H-S, et al. The use of submicron/nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice. Biomaterials. 2010;31(19):5199–207. doi:10.1016/j.biomaterials.2010.03.002.
O’Donnell PB, McGinity JW. Preparation of microspheres by the solvent evaporation technique. Adv Drug Deliv Rev. 1997;28(1):25–42. doi:10.1016/s0169-409x(97)00049-5.
Auerbach R, Akhtar N, Lewis RL, Shinners BL. Angiogenesis assays: problems and pitfalls. Cancer Metastasis Rev. 2000;19(1–2):167–72.
Toktas ZO, Akgun E, Ozkan A, Bozkurt SU, Bekiroglu N, Seker A, et al. Relationship of angiogenic potential with clinical features in cranial meningiomas: a corneal angiogenesis study. Neurosurgery. 2010;67(6):1724–32. doi:10.1227/NEU.0b013e3181f9f310. discussion 32.
Konya D, Yildirim O, Kurtkaya O, Kilic K, Black PM, Pamir MN, et al. Testing the angiogenic potential of cerebrovascular malformations by use of a rat cornea model: usefulness and novel assessment of changes over time. Neurosurgery. 2005;56(6):1339–45. discussion 45-6.
Kilic K, Konya D, Kurtkaya O, Sav A, Pamir MN, Kilic T. Inhibition of angiogenesis induced by cerebral arteriovenous malformations using gamma knife irradiation. J Neurosurg. 2007;106(3):463–9. doi:10.3171/jns.2007.106.3.463.
Ozkan A, Guduk M, Atabay KD, Uyar SB, Seker A, Konya D, et al. High angiogenic potential in an in vivo rat corneal model is associated with shorter disease-free survival in low-grade oligodendrogliomas. J Clin Neurosci. 2010;18(1):109–13. doi:10.1016/j.jocn.2010.05.034.
Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N. Angiogenesis assays: a critical overview. Clin Chem. 2003;49(1):32–40.
Jain RK, Schlenger K, Hockel M, Yuan F. Quantitative angiogenesis assays: progress and problems. Nat Med. 1997;3(11):1203–8.
Fahlbusch R, Honegger J, Paulus W, Huk W, Buchfelder M. Surgical treatment of craniopharyngiomas: experience with 168 patients. J Neurosurg. 1999;90(2):237–50.
Karavitaki N, Cudlip S, Adams CB, Wass JA. Craniopharyngiomas. Endocr Rev. 2006;27(4):371–97. doi:10.1210/er.2006-0002.
Vidal S, Scheithauer BW, Kovacs K, Lloyd RV. Angiogenesis and the growth potential of craniopharyngiomas. Endocr Pathol. 2005;16(3):219–28. EP:16:3:219 [pii].
Fakhrai N, Neophytou P, Dieckmann K, Nemeth A, Prayer D, Hainfellner J, et al. Recurrent spinal ependymoma showing partial remission under Imatimib. Acta Neurochir. 2004;146(11):1255–8. doi:10.1007/s00701-004-0374-5.
Bihorel S, Camenisch G, Gross G, Lemaire M, Scherrmann J-M. Influence of hydroxyurea on imatinib mesylate (gleevec) transport at the mouse blood-brain barrier. Drug Metab Dispos. 2006;34(12):1945–9. doi:10.1124/dmd.106.010975.
Wen PY, Yung WKA, Lamborn KR, Dahia PL, Wang Y, Peng B, et al. Phase I/II study of ımatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99–08. Clin Cancer Res. 2006;12(16):4899–907. doi:10.1158/1078-0432.ccr-06-0773.
Fredenberg S, Wahlgren M, Reslow M, Axelsson A. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems—a review. Int J Pharm. 2011;415(1–2):34–52. doi:10.1016/j.ijpharm.2011.05.049.
Lee Y-H, Mei F, Bai M-Y, Zhao S, Chen D-R. Release profile characteristics of biodegradable-polymer-coated drug particles fabricated by dual-capillary electrospray. J Controlled Release. 2010;145(1):58–65. doi:10.1016/j.jconrel.2010.03.014.
Berkland C, Kim K, Pack DW. PLG microsphere size controls drug release rate through several competing factors. Pharm Res. 2003;20(7):1055–62.
Acknowledgments
Turker Kilic MD PhD is a member of Turkish Academy of Sciences. Scientific activities of Turker Kilic are supported by TUBA. Imatinib mesylate has been kindly provided by Novartis, Basel. This study was supported by both TUBA and The Scientific and Technological Research Council of Turkey (TUBITAK) 1001 research grants (SBAG-108S062).
Conflict of interest
The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Karal-Yilmaz, O., Ozkan, A., Akgun, E. et al. Controlled release of imatinib mesylate from PLGA microspheres inhibit craniopharyngioma mediated angiogenesis. J Mater Sci: Mater Med 24, 147–153 (2013). https://doi.org/10.1007/s10856-012-4784-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10856-012-4784-2